Inventor · disambiguated record
Brenda F. Baker
Also filed as: BAKER BRENDA · BAKER BRENDA F · FREIER SUSAN M
43 granted patents·73 pending applications·1,929 citations·filing 1993–2021
98Inventor score
Files withISIS PHARMACEUTICALS INC51BENNETT C F7IONIS PHARMACEUTICALS INC5ALLERSON CHARLES4BIOGEN MA INC3
Top patents by PatentIndex Score
116 records- 0198US6210892B1Alteration of cellular behavior by antisense modulation of mRNA processingISIS PHARMACEUTICALS INC·Filed 1999·Granted Apr 3, 2001·358 cites·31 claims
- 0297US8361977B2Compositions and methods for modulation of SMN2 splicingISIS PHARMACEUTICALS INC·Filed 2006·Granted Jan 29, 2013·62 cites·48 claims
- 0397US7339051B2Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)ISIS PHARMACEUTICALS INC·Filed 2004·Granted Mar 4, 2008·158 cites·18 claims
- 0496US10266825B2Compositions comprising alternating 2′-modified nucleosides for use in gene modulationIONIS PHARMACEUTICALS INC·Filed 2017·Granted Apr 23, 2019·10 cites·21 claims
- 0596US5789573AAntisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2ISIS PHARMACEUTICALS INC·Filed 1996·Granted Aug 4, 1998·262 cites·4 claims
- 0695US7321828B2System of components for preparing oligonucleotidesISIS PHARMACEUTICALS INC·Filed 1998·Granted Jan 22, 2008·216 cites·4 claims
- 0794US8946183B2Compositions and methods for modulation of SMN2 splicingISIS PHARMACEUTICALS INC·Filed 2012·Granted Feb 3, 2015·12 cites·14 claims
- 0893US5985558AAntisense oligonucleotide compositions and methods for the inibition of c-Jun and c-FosISIS PHARMACEUTICALS INC·Filed 1997·Granted Nov 16, 1999·101 cites·44 claims
- 0992US9708610B2Compositions comprising alternating 2′-modified nucleosides for use in gene modulationIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jul 18, 2017·6 cites·19 claims
- 1092US6228642B1Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted May 8, 2001·91 cites·14 claims
- 1191US7919612B22′-substituted oligomeric compounds and compositions for use in gene modulationsISIS PHARMACEUTICALS INC·Filed 2003·Granted Apr 5, 2011·14 cites·12 claims
- 1291US7884086B2Conjugates for use in hepatocyte free uptake assaysISIS PHARMACEUTICALS INC·Filed 2005·Granted Feb 8, 2011·21 cites·17 claims
- 1391US6096722AAntisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseasesISIS PHARMACEUTICALS INC·Filed 1998·Granted Aug 1, 2000·106 cites·22 claims
- 1491US6007995AAntisense inhibition of TNFR1 expressionISIS PHARMACEUTICALS INC·Filed 1998·Granted Dec 28, 1999·88 cites·11 claims
- 1590US8604183B2Compositions comprising alternating 2′-modified nucleosides for use in gene modulationALLERSON CHARLES·Filed 2003·Granted Dec 10, 2013·20 cites·24 claims
- 1688US6080580AAntisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expressionISIS PHARMACEUTICALS INC·Filed 1998·Granted Jun 27, 2000·86 cites·11 claims
- 1787US6312900B1Antisense oligonucleotide compositions and methods for the modulation of activating protein 1ISIS PHARMACEUTICALS INC·Filed 1999·Granted Nov 6, 2001·59 cites·34 claims
- 1886US9150606B2Compositions comprising alternating 2'-modified nucleosides for use in gene modulationALLERSON CHARLES·Filed 2005·Granted Oct 6, 2015·9 cites·21 claims
- 1985US7812149B22′-Fluoro substituted oligomeric compounds and compositions for use in gene modulationsISIS PHARMACEUTICALS INC·Filed 2003·Granted Oct 12, 2010·12 cites·22 claims
- 2085US6372433B1Antisense modulation of inhibitor of DNA binding-1 expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Apr 16, 2002·22 cites·13 claims
- 2184US7790691B2Double stranded compositions comprising a 3′-endo modified strand for use in gene modulationISIS PHARMACEUTICALS INC·Filed 2004·Granted Sep 7, 2010·12 cites·20 claims
- 2282US9150605B2Compositions comprising alternating 2′-modified nucleosides for use in gene modulationALLERSON CHARLES·Filed 2004·Granted Oct 6, 2015·9 cites·22 claims
- 2382US6159734AAntisense modulation of peroxisome proliferator-activated receptor gamma expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Dec 12, 2000·16 cites·13 claims
- 2480US5442049AOligonucleotides for modulating the effects of cytomegalovirus infectionsISIS PHARMACEUTICALS INC·Filed 1993·Granted Aug 15, 1995·57 cites·1 claims
- 2577US2022162603A1Compositions comprising alternating 2'-modified nucleosides for use in gene modulationIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2676US2020181613A1Compositions and methods for modulation of smn2 splicingBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 2774US11078485B2Compositions comprising alternating 2′-modified nucleosides for use in gene modulationIONIS PHARMACEUTICALS INC·Filed 2019·Granted Aug 3, 2021·0 cites·7 claims
- 2874US6399379B1Antisense modulation of interleukin 12 p35 subunit expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Jun 4, 2002·2 cites·26 claims
- 2972US8163477B2Nuclease-based method for detecting and quantitating oligonucleotidesYU ZHENGRONG·Filed 2003·Granted Apr 24, 2012·5 cites·14 claims
- 3070US6355438B1Method for quantitating oligonucleotidesISIS PHARMACEUTICALS INC·Filed 2000·Granted Mar 12, 2002·4 cites·35 claims
- 3170US2004197814A1System of components for preparing oligonucleotidesFiled 2004·Application pending·0 cites
- 3270US2015353929A1Compositions and methods for modulation of smn2 splicingISIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3368US2018291376A1Compositions and methods for modulation of smn2 splicingBIOGEN MA INC·Filed 2017·Application pending·0 cites
- 3468US2005033524A1Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulationFiled 2003·Application pending·0 cites
- 3565US8791083B2Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometryMONIA BRETT P·Filed 2009·Granted Jul 29, 2014·0 cites·21 claims
- 3665US6054316AAntisense inhibition of ETs-2 expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Apr 25, 2000·17 cites·12 claims
- 3765US2017088835A1Compositions and methods for modulation of smn2 splicingBIOGEN MA INC·Filed 2016·Application pending·0 cites
- 3864US6171860B1Antisense inhibition of rank expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Jan 9, 2001·18 cites·23 claims
- 3964US5948680AAntisense inhibition of Elk-1 expressionISIS PHARMACEUTICALS INC·Filed 1998·Granted Sep 7, 1999·16 cites·12 claims
- 4064US2006069518A1Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulationISIS PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 4164US2005153924A1Antisense modulation of interferon gamma receptor 2Filed 2004·Application pending·0 cites
- 4263US7700574B2Modulation of RANKL expressionISIS PHARMACEUTICALS INC·Filed 2004·Granted Apr 20, 2010·1 cites·16 claims
- 4363US2006074043A1Antisense modulation of matrix metalloproteinase 1 expressionMONIA BRETT P·Filed 2005·Application pending·0 cites
- 4463US2003113739A1System of components for preparing oligonucleotidesFiled 2002·Application pending·0 cites
- 4562US2008039618A1Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulationALLERSON CHARLES·Filed 2007·Application pending·0 cites
- 4661US6015712AAntisense modulation of FADD expressionISIS PHARMACEUTICALS INC·Filed 1999·Granted Jan 18, 2000·15 cites·24 claims
- 4761US2005227938A1Antisense modulation of TFAP2C expressionBENNETT C F·Filed 2004·Application pending·0 cites
- 4861US2003194738A1Antisense oligonucleotide compositions and methods for the modulation of activating protein 1Filed 2003·Application pending·0 cites
- 4959US6001652AAntisense modulation of cREL expressionISIS PHARMACEUTICALS INC·Filed 1998·Granted Dec 14, 1999·12 cites·10 claims
- 5059US2004121977A1Antisense modulation of activating transcription factor 3 expressionFiled 2003·Application pending·0 cites
Showing the top 50 of 116 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →